Crescent Biopharma, Inc. (CBIO) |
| 12.04 0.99 (8.96%) 01-14 13:23 |
| Open: | 11.15 |
| High: | 12.195 |
| Low: | 11.07 |
| Volume: | 47,201 |
| Market Cap: | 167(M) |
| PE Ratio: | 0 |
| Exchange: | NASDAQ Capital Market |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 15.58 |
| Resistance 1: | 13.66 |
| Pivot price: | 11.50 |
| Support 1: | 10.56 |
| Support 2: | 8.79 |
| 52w High: | 37 |
| 52w Low: | 9.81 |
Crescent Biopharma, Inc., an oncology company, develops therapies for cancer patients. Its pipeline includes a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates to treat solid tumors. The company is headquartered in Waltham, Massachusetts.
Financials
| EPS | 0.000 |
| Book Value | 5.760 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.000 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | 0.00 |
| Return on Assets (ttm) | 0.0 |
| Return on Equity (ttm) | 0.0 |
Company news
Mon, 05 Jan 2026
Two experimental cancer drugs cleared to begin human trials in U.S., China - Stock Titan
Thu, 18 Dec 2025
Crescent Biopharma Announces Grants of Inducement Awards - GlobeNewswire
Thu, 04 Dec 2025
Crescent Biopharma (Nasdaq: CBIO) raises $185M to fund 3 solid tumor programs into 2028 - Stock Titan
Thu, 04 Dec 2025
Crescent Biopharma Announces Transformational Partnership with Kelun-Biotech and $185 Million Private Placement, Accelerating and Expanding Global Pipeline of Next Generation Therapeutics for Solid Tumors - The Manila Times
Thu, 04 Dec 2025
Crescent Biopharma partners with Kelun-Biotech, raises $185 million - Investing.com
Thu, 04 Dec 2025
Crescent, Kelun-Biotech Sign Oncology Deal; Crescent To Raise $185 Mln; Stock Up - Nasdaq
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
